Bayesian Capital Management’s Frontline FRO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-25,500
Closed -$310K 899
2022
Q4
$310K Buy
25,500
+6,400
+34% +$82.2K 0.05% 475
2022
Q3
$209K Buy
+19,100
New +$209K 0.04% 516
2022
Q2
Sell
-13,265
Closed -$117K 886
2022
Q1
$117K Buy
+13,265
New +$105K 0.02% 689
2018
Q4
Sell
-11,900
Closed -$69K 661
2018
Q3
$69K Sell
11,900
-3,000
-20% -$15.8K 0.01% 597
2018
Q2
$87K Buy
+14,900
New +$75.1K 0.02% 559
2016
Q1
Sell
-3,980
Closed -$60K 378
2015
Q4
$60K Buy
+3,980
New +$60.6K 0.09% 222

Other funds holding FRO

Bayesian Capital Management's FRO Position: Q1 2023 in Review

Bayesian Capital Management sold out of Frontline (FRO) in Q1 2023, closing a stake of 25,500 shares — an estimated $310K sold.

Bayesian Capital Management first reported a position in FRO in Q4 2015 and held it in 6 quarters. The position peaked at $310K in Q4 2022. 163 funds tracked by Wall St. Rank hold FRO as of Q1 2023.

  • Bayesian Capital Management reported no remaining Frontline position as of Q1 2023 after selling out during the quarter.
  • Bayesian Capital Management sold 25,500 Frontline shares in Q1 2023, an estimated $310K.
  • Bayesian Capital Management first reported a position in Frontline in Q4 2015 and held it in 6 quarters.
  • Bayesian Capital Management's Frontline position peaked at $310K in Q4 2022.
  • 163 funds tracked by Wall St. Rank held Frontline as of Q1 2023.

Based on Bayesian Capital Management's 13F filing for Q1 2023, filed 15 May 2023.